- Home
- DTST vs BOLD Comparison
DTST vs BOLD Comparison
Compare DTST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- BOLD
- Stock Information
- Founded
- DTST 2001
- BOLD 2018
- Country
- DTST United States
- BOLD United States
- Employees
- DTST N/A
- BOLD N/A
- Industry
- DTST EDP Services
- BOLD
- Sector
- DTST Technology
- BOLD
- Exchange
- DTST Nasdaq
- BOLD Nasdaq
- Market Cap
- DTST 28.2M
- BOLD 30.3M
- IPO Year
- DTST N/A
- BOLD 2024
- Fundamental
- Price
- DTST $3.88
- BOLD $1.18
- Analyst Decision
- DTST
- BOLD Buy
- Analyst Count
- DTST 0
- BOLD 3
- Target Price
- DTST N/A
- BOLD $4.00
- AVG Volume (30 Days)
- DTST 48.0K
- BOLD 82.5K
- Earning Date
- DTST 05-15-2025
- BOLD 05-09-2025
- Dividend Yield
- DTST N/A
- BOLD N/A
- EPS Growth
- DTST N/A
- BOLD N/A
- EPS
- DTST 0.02
- BOLD N/A
- Revenue
- DTST $25,219,312.00
- BOLD N/A
- Revenue This Year
- DTST $12.57
- BOLD N/A
- Revenue Next Year
- DTST $9.29
- BOLD N/A
- P/E Ratio
- DTST $160.15
- BOLD N/A
- Revenue Growth
- DTST N/A
- BOLD N/A
- 52 Week Low
- DTST $2.93
- BOLD $1.06
- 52 Week High
- DTST $6.96
- BOLD $10.13
- Technical
- Relative Strength Index (RSI)
- DTST 54.72
- BOLD N/A
- Support Level
- DTST $3.66
- BOLD N/A
- Resistance Level
- DTST $3.95
- BOLD N/A
- Average True Range (ATR)
- DTST 0.19
- BOLD 0.00
- MACD
- DTST -0.01
- BOLD 0.00
- Stochastic Oscillator
- DTST 54.90
- BOLD 0.00
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.